abstract |
FIELD: pharmaceutical industry.SUBSTANCE: invention relates to new crystalline forms and salt forms of the TGF-βR1 inhibitor, as well as their use in the preparation of drugs for the treatment of cancer.EFFECT: new crystalline forms of the compounds of formula (I), as well as compounds of formulas (II), (IV), (V), (VI), which have the properties of the TGF-βR1 inhibitor and can be used for the treatment of cancer mediated by inhibition of the TGF- βR1.19 cl, 7 dwg, 5 tbl, 13 ex |